Processa Acquires Vidya for BTK Inhibitor in $200M Deal

What happened

Processa Pharmaceuticals completed an all-stock acquisition of Vidya Therapeutics, adding VT-7208, an oral BTK inhibitor, to its pipeline. Vidya stockholders received approximately 558,398 shares of Processa common stock and 142,744 shares of Series A preferred stock (convertible to roughly 142.7 million common shares). Simultaneously, Processa raised approximately $200 million through a private placement led by Bain Capital Life Sciences, Janus Henderson Investors, RA Capital Management, and other institutional investors. The financing investors will receive approximately 163,775 shares of Series A preferred stock at $1,221.19 per share (equivalent to about $1.22 per common share on an as-converted basis). The private placement is expected to close on July 30, 2026. Following the transaction, existing Processa shareholders will own approximately 0.9% of the combined company on a fully diluted basis, with former Vidya equity holders owning about 46% and private placement investors holding roughly 52.6%. Vidya founder Sheila Gujrathi joined Processa's board as part of the transaction.

Why it matters

The acquisition marks a strategic shift for Processa, pivoting from its oncology focus to the autoimmune space with a potentially differentiated BTK inhibitor. VT-7208 is described as a next-generation, CNS-penetrant, covalent BTK inhibitor designed to achieve effective target engagement at lower doses than earlier BTK inhibitors and minimize off-target kinase activity, which the companies believe may reduce hepatotoxicity risk-a concern with existing BTK inhibitors like Novartis' Rhapsido. The drug has completed Phase 1 trials demonstrating sustained target engagement in cerebrospinal fluid and the body, with no serious adverse events observed. The $200 million in funding will enable Processa to advance three Phase 2 programs in parallel rather than sequentially, potentially evaluating VT-7208's efficacy across allergic, autoimmune, and neuroinflammatory conditions within a concentrated timeframe. Phase 2 studies in food allergy and CSU are planned to begin in 2H 2026, with an RMS trial starting in 1H 2027. Top-line data readouts are expected in 2H 2027 (food allergy), 1H 2028 (CSU), and 2H 2028 (RMS). The financing is projected to fund operations into 2H 2029.

Bigger picture

The acquisition positions Processa to compete in the growing BTK inhibitor market, particularly in indications where Novartis' Rhapsido has already gained traction. Rhapsido became the first BTK inhibitor approved for CSU in 2025 and has shown promising Phase 2 data in food allergy, with Phase 3 multiple sclerosis readouts expected in 2026. BTK plays a critical role in mast cell degranulation and B cell-mediated autoantibody production, making BTK inhibitors attractive for treating both allergic and autoimmune forms of CSU. However, earlier BTK inhibitors have faced challenges with safety, particularly liver toxicity. VT-7208's design-emphasizing selectivity, CNS penetration, and lower dosing-aims to address these limitations. The ability to penetrate the central nervous system is particularly important for RMS, where the drug must reach the brain and spinal cord to directly address inflammatory processes. The transaction reflects significant investor confidence in VT-7208's potential, as evidenced by the oversubscribed $200 million private placement and the participation of prominent healthcare-focused funds. The ownership structure post-transaction-with existing Processa shareholders owning less than 1%-indicates this is effectively a reverse merger, with Vidya's assets and backers taking control of the combined entity.

What to watch

Key near-term catalysts include the initiation of Phase 2 trials in food allergy and CSU (expected 2H 2026) and the start of the RMS trial (1H 2027). Top-line data readouts will provide critical validation of VT-7208's efficacy and safety profile: food allergy results are anticipated in 2H 2027, CSU data in 1H 2028, and RMS outcomes in 2H 2028. Investors should monitor whether VT-7208 demonstrates differentiation from Rhapsido and other BTK inhibitors, particularly in terms of efficacy at lower doses and reduced hepatotoxicity risk. The closing of the private placement on July 30, 2026, and subsequent shareholder approval for the conversion of Series A preferred stock into common stock will also be important milestones. Additionally, Processa's plans for its existing assets, including PCS499 and PCS12852, and any strategic decisions regarding these programs could impact the company's overall trajectory.